modelDupilumab
Extends from Pharmacolibrary.Drugs.ATC.D.D11AH05.
Information
| name: | Dupilumab | |
| ATC code: | D11AH05 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 600 | mg |
| volume of distribution: | 4.8 | L |
| clearance: | 0.16 | L/day |
| other parameters in model implementation | ||
Dupilumab is a fully human monoclonal antibody that inhibits signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) by binding to the IL-4 receptor alpha subunit. It is used in the treatment of moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, and is an FDA and EMA approved biologic drug.
Pharmacokinetics
Pharmacokinetics reported from adult patients with atopic dermatitis; population PK analyses evaluated after subcutaneous administration in healthy or affected subjects.
References
Kamal, MA, et al., & Arima, K (2022). Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis. Clinical and translational science 15(10) 2342–2354. DOI:10.1111/cts.13363 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35986664
Cork, MJ, et al., & Levit, NA (2023). Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis. Dermatology and therapy 13(11) 2697–2719. DOI:10.1007/s13555-023-01016-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37750994
Zhang, L, et al., & Lu, Q (2021). Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma. CPT: pharmacometrics & systems pharmacology 10(8) 941–952. DOI:10.1002/psp4.12667 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34313019
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)